Retrieve available abstracts of 26 articles: HTML format
Single Articles
February 2025
SEKAR RR, Zebib L, Stensland KD, Herrel LA, et al Structural inequities in the availability of prostate cancer clinical trial
opportunities.
J Natl Cancer Inst. 2025 Feb 26:djaf047. doi: 10.1093. PubMedAbstract available
January 2025
TOSOIAN JJ Active surveillance for prostate cancer: How active is too active?
J Natl Cancer Inst. 2025 Jan 27:djae342. doi: 10.1093. PubMed
MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based
multicountry study of 5 cancers.
J Natl Cancer Inst. 2025;117:120-133. PubMedAbstract available
GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al Pan-cancer genomic analysis reveals FOXA1 amplification is associated with
adverse outcomes in non-small cell lung, prostate, and breast cancers.
J Natl Cancer Inst. 2025;117:188-197. PubMedAbstract available
November 2024
HAMMARLUND N, Holt SK, Etzioni R, Morehead D, et al The Association of Where Patients with Prostate Cancer Live and Receive Care on
Racial Treatment Inequities.
J Natl Cancer Inst. 2024 Nov 20:djae302. doi: 10.1093. PubMedAbstract available
ZHAO Y, Gulati R, Yang Z, Newcomb L, et al Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer:
Implications for Relabeling.
J Natl Cancer Inst. 2024 Nov 20:djae296. doi: 10.1093. PubMedAbstract available
October 2024
COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al When is prostate cancer really cancer?
J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093. PubMedAbstract available
KATKI HA, Prorok PC, Castle PE, Minasian LM, et al Increasing power in screening trials by testing control-arm specimens:
application to multicancer detection screening.
J Natl Cancer Inst. 2024;116:1675-1682. PubMedAbstract available
LIU S, Rivero SL, Zhang B, Shen K, et al BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate
adenocarcinoma initiation and progression.
J Natl Cancer Inst. 2024;116:1598-1611. PubMedAbstract available
September 2024
EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al Disparities in the Utilization of MRI for Prostate Cancer Detection: A
Population-Based Study.
J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093. PubMedAbstract available
August 2024
KATKI HA, Prorok PC, Castle PE, Minasian LM, et al Increasing power in screening trials by testing control-arm specimens:
application to multicancer detection screening.
J Natl Cancer Inst. 2024;116:1280-1287. PubMedAbstract available
July 2024
FARAJ KS, Oerline M, Kaufman SR, Dall C, et al Adverse events in men with advanced prostate cancer treated with androgen
biosynthesis inhibitors and androgen receptor inhibitors.
J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093. PubMedAbstract available
June 2024
DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al Predicting prostate cancer grade reclassification on active surveillance using a
deep Learning-Based grading algorithm.
J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093. PubMedAbstract available
May 2024
BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor
Antagonists.
J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093. PubMedAbstract available
February 2024
BASU A, Rais-Bahrami S Genomic risk scores in prostate cancer: polygenic yes, but are they
poly-ancestral?
J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093. PubMed
LAO Y, Guan X, Wang J, Bai Y, et al RE: Risks of depression, anxiety, and suicide in partners of men with prostate
cancer: a national cohort study.
J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093. PubMed
January 2024
LEE KM, Nelson T, Bryant A, Teerlink C, et al Genetic risk and likelihood of prostate cancer detection on first biopsy by
ancestry.
J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093. PubMedAbstract available
WILKINSON S, Sowalsky AG Defining biology and recurrence risk in prostate cancers treated by neoadjuvant
chemohormonal therapy.
J Natl Cancer Inst. 2024;116:12-14. PubMed
FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al Changes in cancer-related mortality during the COVID-19 pandemic in the United
States.
J Natl Cancer Inst. 2024;116:167-169. PubMedAbstract available
December 2023
CRUMP C, Stattin P, Brooks JD, Sundquist J, et al Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate
Cancer: A National Cohort Study.
J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093. PubMedAbstract available
November 2023
FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al Actigraphy-derived measures of sleep and risk of prostate cancer in the UK
Biobank.
J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093. PubMedAbstract available
COOPERBERG MR Can early prostate cancer screening help address mortality disparities among
Black men?
J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093. PubMed
October 2023
HU S, Chang CP, Snyder J, Deshmukh V, et al Mental health outcomes in a population-based cohort of patients with prostate
cancer.
J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093. PubMedAbstract available
MA T, Jin L, Bai S, Liu Z, et al Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate
Cancer Progression.
J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093. PubMedAbstract available
September 2023
KENSLER KH, Johnson R, Morley F, Albrair M, et al Prostate Cancer Screening in African American Men: A Review of the Evidence.
J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093. PubMedAbstract available
SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3
CALGB 90203 trial.
J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093. PubMedAbstract available